AbbVie Inc. (ABBV)
AbbVie to buy Alzheimer's therapy developer Aliada Therapeutics for $1.4 bln
U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.
3 Dividend Growth Stocks You Can Buy and Hold Forever
These healthcare stocks have fantastic dividend track records.
Curious about AbbVie (ABBV) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AbbVie (ABBV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
These stocks yield between 2.8% and 3.3% in dividends.
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know
In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.
AbbVie: Expect A Beat-And-Raise Q3 2024
AbbVie will report Q3 2024 results next week and I expect to see a beat-and-raise quarter. The outperformance should be driven by top growth products Skyrizi and Rinvoq, the strong performance of neuroscience and oncology segments and by the return to growth of the aesthetics segment. I also expect the company to increase the full-year revenue guidance by $300-500 million.
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie: Strong Dividends But Humira Disappoints
Healthcare stocks are both defensive and present a mean reversion opportunity, making them attractive for risk-averse investors. Revenue exposure analysis shows consistent growth trends over 10 years, indicating stability and resilience but downward over 5. Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.
3 Growth Stocks That Could Be Bargain Buys Right Now
These stocks trade at less than 20 times their estimated future profits.
